Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

October 31, 2019

Study Completion Date

December 31, 2030

Conditions
Non-Hodgkin's LymphomaB-Cell ALLB-Cell CLL
Interventions
GENETIC

CD19.CAR-CD28Z T Cells - dose escalation 2

"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"

GENETIC

CD19.CAR-CD28Z T Cells - dose escalation 1

"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER